Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2018

View Archived Issues

Synthetic lethal target for sarcomas discovered

Onc: orphan noncoding, oncology

Template-free Cas9 for accurate editing

Safety, tolerability and immunogenicity of a live-attenuated, measles-vectored chikungunya vaccine

MSC-derived exosomes show promise in preclinical model of AD

Negative allosteric modulator for the CB1 receptor, ABM-300, active in psychiatric disorder models

Proteins from hepatocyte-derived exosomes predict idiosyncratic drug-induced liver injury

Dysregulation of ERG3 channels contributes to epilepsy in mice

Newly discovered homozygous loss-of-function mutation in CYBC1 causes chronic granulomatous disease

CM-EX-137, a CRAC channel inhibitor with proven efficacy in ischemic stroke model

MiRNA deregulation contributes to autism spectrum disorders

Aduro BioTech, Novartis describe stimulator of interferon genes protein agonists

Celgene patents GLP-1 receptor agonists

Medigene and LUMC enter exclusive license agreement to develop novel HA-1-specific TCR

Helperby and UCLA announce collaboration on new fast track antibiotic therapies

Phase I study of TG-1701 open for enrollment for patients with B-cell malignancies

Phase IIa and IIb data reported for RENCA cells encapsulated in agarose macrobeads

DeuteRx presents first-in-human results for DRX-065

New enacyloxin derivatives developed at the University of Warwick

Cadila Healthcare identifies nuclear receptor RORgammaT inverse agonists

Boehringer Ingelheim describes new plasma kallikrein inhibitors

Tetracycline derivatives synthesized at Novintum Biotechnology

PD-1/PD-L1 interaction inhibitors discovered at Nanjing Sanhome Pharmaceutical

Imugene prepares to advance IMU-131 into phase II gastric cancer study

DNAtrix and Valo collaborate to develop armed oncolytic vaccine for cancer therapy

Calliditas begins phase III study of Nefecon in IgA nephropathy

United Neuroscience presents preclinical data on Parkinson's disease vaccine candidate UB-312

FDA approves Oralair to treat grass pollen-induced allergic rhinitis in pediatric patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...